Metagenomi Therapeutics (MGX) investor relations material

Executive summary

• Focused on in vivo genome editing, reprioritizing pipeline to advance lead programs with highest probability of success and financial discipline.

• Lead program MGX-001 targets hemophilia A, with preclinical data showing curative potential and IND submission planned for Q4 2026; first-in-human studies planned for 2027.

• Collaboration with Ionis Pharmaceuticals continues, with four Wave 1 targets in lead optimization for cardiometabolic indications.

• Publication in Nature Structural & Molecular Biology highlights MG119-28, a proprietary compact CRISPR nuclease with enhanced genome editing efficiency.

• Strategic restructuring in late 2025 included a 25% workforce reduction and CEO transition.

Financial highlights

• Collaboration revenue was $1.2 million for Q1 2026, down from $4.1 million in Q1 2025, due to lower Ionis and Affini-T revenue.

• Net loss for Q1 2026 was $23.1 million, compared to $25.0 million in Q1 2025; net loss per share was $0.61 versus $0.68 year-over-year.

• Research and development expenses decreased to $19.3 million from $25.1 million year-over-year.

• General and administrative expenses were $6.5 million, slightly down from $6.8 million year-over-year.

• Cash, cash equivalents, and marketable securities totaled $140.2 million as of March 31, 2026.

Outlook and guidance

• Existing cash and investments expected to fund operations for at least the next 12 months; runway projected through Q4 2027.

• Regulatory submission for MGX-001 IND is expected in Q4 2026, with clinical trials to begin in 2027 pending clearance.

• Anticipates continued substantial losses as programs advance toward clinical development.

• Additional funding will be required for future development, regulatory, and commercialization activities.

• Plans to expand the pipeline leveraging proprietary gene editing capabilities in site-specific deletion, insertion, and correction.